<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04270214</url>
  </required_header>
  <id_info>
    <org_study_id>115308</org_study_id>
    <nct_id>NCT04270214</nct_id>
  </id_info>
  <brief_title>Conversion to Dysport in Cervical Dystonia Patients</brief_title>
  <official_title>Conversion and Kinematic-optimization of Dysport in Cervical Dystonia Participants</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Western University, Canada</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Western University, Canada</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The first line of therapy for cervical dystonia patients is botulinum toxin injections,&#xD;
      however injection parameter determination and optimization are challenging for physicians to&#xD;
      do. In addition, some patients receiving this treatment long-term experience short duration&#xD;
      of relief. Thus, Dysport (Ipsen Biopharmaceuticals), another BoNT-A formulation, may increase&#xD;
      the duration of clinical benefit. The objective of this study is to compare the wearing off&#xD;
      time of their original BoNT-A formulation (same injection parameters for at least 3 cycles)&#xD;
      and the optimized treatment of Dysport (after 2 injection cycles). Ideally, the clinical&#xD;
      benefits should last 2.5 - 3 months as injections are administered every 3 months. Conversion&#xD;
      to Dysport will be conducted and optimization of Dysport dosing will be done using our&#xD;
      sensor-technology assessment.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">April 2020</start_date>
  <completion_date type="Anticipated">January 2022</completion_date>
  <primary_completion_date type="Anticipated">June 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>waning effect</measure>
    <time_frame>within 12 weeks of treatment</time_frame>
    <description>telephone call report of when participant perceives benefit of treatment is wearing off</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>objective measures of CD severity</measure>
    <time_frame>4-weeks and 12-weeks post-treatment</time_frame>
    <description>Kinematic sensor technology is used to measure CD symptoms (neck pulling and/or tremor). Sensors coupled with computer-assisted analysis can measure degrees of deviation from neutral head/neck position and angular root mean square tremor/dystonic jerks amplitude in each plane of motion (vertical, lateral, rotational).</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">35</enrollment>
  <condition>Cervical Dystonia</condition>
  <arm_group>
    <arm_group_label>Dysport</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Single arm study, all participants will receive Dysport injections</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dysport Injectable Product</intervention_name>
    <description>Dysport injections optimized using kinematics</description>
    <arm_group_label>Dysport</arm_group_label>
    <other_name>abobotulinumtoxinA</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients with cervical dystonia&#xD;
&#xD;
          -  Patients experiencing early waning off (benefit for up to 8 weeks) of their current&#xD;
             BoNT-A treatment (stable for at least 3 treatments)&#xD;
&#xD;
          -  Only those that want to switch to Dysport will be included.&#xD;
&#xD;
          -  No prior exposure to Dysport&#xD;
&#xD;
          -  Able to come for multiple visits&#xD;
&#xD;
          -  Patient's injection parameters are stable for â‰¥3 cycles&#xD;
&#xD;
          -  Patient can provide written consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Unable to come for study visits&#xD;
&#xD;
          -  Not interested in switching&#xD;
&#xD;
          -  Total dose of original BoNT-A formulation exceeds 360 U of Botox or 300 U of Xeomin&#xD;
&#xD;
          -  Pregnant and/or lactating females&#xD;
&#xD;
          -  Known resistance to any BoNT-A&#xD;
&#xD;
          -  Known hypersensitivity to BoNT-A or related compounds, or any component in the study&#xD;
             drug formulation&#xD;
&#xD;
          -  In the opinion of the investigator, the subject is unable and/or unwilling to comply&#xD;
             fully with the protocol and the study instructions&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Olivia Samotus</last_name>
    <phone>519-685-8500</phone>
    <phone_ext>32059</phone_ext>
    <email>olivia.samotus@lhsc.on.ca</email>
  </overall_contact>
  <location>
    <facility>
      <name>London Health Sciences Centre</name>
      <address>
        <city>London</city>
        <state>Ontario</state>
        <zip>N6A 5A5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>February 12, 2020</study_first_submitted>
  <study_first_submitted_qc>February 12, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">February 17, 2020</study_first_posted>
  <last_update_submitted>February 18, 2020</last_update_submitted>
  <last_update_submitted_qc>February 18, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 21, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Western University, Canada</investigator_affiliation>
    <investigator_full_name>Mandar Jog</investigator_full_name>
    <investigator_title>Movement disorders neurologist</investigator_title>
  </responsible_party>
  <keyword>botulinum toxin type A</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dystonia</mesh_term>
    <mesh_term>Dystonic Disorders</mesh_term>
    <mesh_term>Torticollis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>abobotulinumtoxinA</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

